
1. malar j. 2020 jan 21;19(1):37. doi: 10.1186/s12936-020-3126-y.

late clinical failure associated cytochrome b codon 268 mutation during
treatment falciparum malaria atovaquone-proguanil traveller returning 
from congo.

massamba l(1), madamet m(2)(3)(4)(5), benoit n(2)(3)(4)(5), chevalier a(1), fonta
i(2)(3)(4)(5), mondain v(6), jeandel py(7), amalvict r(2)(3)(4)(5), delaunay
p(1)(8), mosnier j(2)(3)(4)(5), marty p(1)(9), pomares c(1)(9), pradines
b(10)(11)(12)(13).

author information: 
(1)parasitologie mycologie, centre hospitalo-universitaire de nice, université de
la côte d'azur, nice, france.
(2)unité parasitologie et entomologie, département de microbiologie et de
maladies infectieuses, institut de recherche biomédicale des armées, marseille,
france.
(3)aix marseille université, ird, ssa, ap-hm, vitrome, marseille, france.
(4)ihu méditerranée infection, marseille, france.
(5)centre national de référence du paludisme, marseille, france.
(6)infectiologie, centre hospitalo-universitaire de nice, université de la côte
d'azur, nice, france.
(7)service de médecine interne, centre hospitalier universitaire de nice, nice,
france.
(8)mivegec, umr ird 224-cnrs 5290-université de montpellier, montpellier, france.
(9)inserm, u1065, centre méditerranéen de médecine moléculaire, faculté de
médecine, virulence microbienne et signalisation inflammatoire, nice, france.
(10)unité parasitologie et entomologie, département de microbiologie et de
maladies infectieuses, institut de recherche biomédicale des armées, marseille,
france. bruno.pradines@gmail.com.
(11)aix marseille université, ird, ssa, ap-hm, vitrome, marseille, france.
bruno.pradines@gmail.com.
(12)ihu méditerranée infection, marseille, france. bruno.pradines@gmail.com.
(13)centre national de référence du paludisme, marseille, france.
bruno.pradines@gmail.com.

background: drug combination atovaquone-proguanil, recommended for
treatment uncomplicated falciparum malaria france. despite high efficacy,
atovaquone-proguanil treatment failures reported. resistance to
cycloguanil, active metabolite proguanil, conferred multiple
mutations plasmodium falciparum dihydrofolate reductase (pfdhfr) and
resistance atovaquone single mutation codon 268 cytochrome b gene
(pfcytb).
case presentation: 47-year-old female, native congo resident in
france, admitted hospital uncomplicated falciparum malaria with
parasitaemia 0.5%, travelling congo (brazzaville pointe noire).
she treated atovaquone-proguanil (250 mg/100 mg) 4 tablets daily 3
consecutive days. day 5 admission released home. however, many
weeks episode, without left france, experienced fever
and intense weakness. day 39 beginning treatment, consulted
for fever, arthralgia, myalgia, photophobia, blurred vision. was
hospitalized uncomplicated falciparum malaria parasitaemia 0.375%
and treated effectively piperaquine-artenimol (320 mg/40 mg) 3 tablets daily
for 3 consecutive days. resistance atovaquone-proguanil suspected. the
y268c mutation detected isolates tested (d39, d42, d47). the
genotyping pfdhfr gene showed triple mutation (n51i, c59r, s108n)
involved cycloguanil resistance.
conclusion: first observation late clinical failure of
atovaquone-proguanil treatment p. falciparum uncomplicated malaria associated 
with pfcytb 268 mutation traveller returning congo. data confirm 
that y268c mutation associated delayed recrudescence 4 weeks 
after initial treatment. although atovaquone-proguanil treatment failures remain 
rare, increased surveillance required. essential declare and
publish well-documented cases treatment failures only
way evaluate level resistance atovaquone.

doi: 10.1186/s12936-020-3126-y 
pmcid: pmc6975030
pmid: 31964401  [indexed medline]

